Brief: Egetis Announces Priority Review Of NDA For Emcitate (Tiratricol) For MCT8 Deficiency

Egetis Therapeutics AB (publ)

27/03/2026 15:43

March 27 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR EMCITATE® (TIRATRICOL) FOR MCT8 DEFICIENCY

PDUFA TARGET ACTION DATE OF SEPT 28, 2026

Source text: ID:nMFNH1qLQ

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))